An official website of the United States government
Government Funding Lapse Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.
The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.
Updates regarding government operating status and resumption of normal operations can be found at opm.gov.
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
Trial Status: active
This is a dose-finding study to assess the safety and preliminary antitumor activity of
Pocenbrodib alone or with Abiraterone acetate, Olaparib or 177Lu-PSMA-617 in patients
with metastatic castration-resistant prostrate cancer (mCRPC).
Inclusion Criteria
≥18 years of age
Histologic documentation of prostate adenocarcinoma
Metastatic disease, documented by imaging. Imaging performed within 56 days prior to Screening is acceptable Key
Exclusion Criteria
Current or prior evidence of any small cell or neuroendocrine histology on the most recent prostate biopsy
Any liver metastases confirmed by biopsy or evidence of lesions >1 cm consistent with liver metastases on imaging
Intervention with any chemotherapy, investigational agent, or other anticancer drug, including enzalutamide, apalutamide, or darolutamide, 14 days prior to Screening or 5 half-live20.
Any other serious underlying medical, psychiatric, psychological, familial, or geographical condition, which in the judgment of the Investigator may interfere with study participation and compliance or place the participant at high risk from treatment-related complicationss from the last dose (whichever is shorter)
Additional locations may be listed on ClinicalTrials.gov for NCT06785636.
